Stojan Arnerstål leads the team at Advokatfirman Vinge, which is well known for handling major, multijurisdictional IP disputes. The group often acts for private equity firms and global pharma companies, and Arnerstål is a key name for clients seeking advice on investments and acquisitions within the healthcare space. IP expert Håkan Borgenhäll regularly acts in patent and SPC disputes, with a strong focus on infringement actions. Christoffer Nordin and Malin Ohlin are key figures within the team with broad expertise in supply, manufacturing, and distribution agreements, and M&A.
L’éditorial du Legal 500
Clients clés
- Eli Lilly and Company
- Bridgepoint Growth
- Fidelio Capital
- Recipharm AB (publ)
- Atlas Antibodies AB
- Tamro AB
- Vimian Group AB (publ)
- Corline Biomedical AB (publ)
- Medivir AB (publ)
- Xspray Pharma AB (publ)
Points forts
- Representing Merck Sharp & Dohme in a complex SPC dispute where KRKA challenges an SPC for Janumet. The case involves novel legal issues regarding dual SPCs for the same patent, with a pivotal referral to the EUCJ.
- Assisting Takeda Pharmaceutical Company Limited with a pending action against Sandoz regarding infringement in one of Takeda’s patents, covering a product to be used in the treatment of ADHD.
- Advising Thermo Fisher Scientific Inc. in connection with its acquisition of Olink Holding AB (publ).
Avocats
Responsable de la pratique
Stojan Arnerstål
Autres avocats clés
Håkan Borgenhäll; Malin Malm Waerme; Christoffer Nordin; Malin Ohlin